Navigation Links
Ambit Announces Presentations At The 55th Annual Meeting Of The American Society Of Hematology (ASH)
Date:12/9/2013

SAN DIEGO, Dec. 9, 2013 /PRNewswire/ -- Ambit Biosciences (Nasdaq: AMBI), a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced four oral presentations given at the 55th Annual ASH Conference in New Orleans, with data highlighting the Company's lead drug candidate, quizartinib. 

Results of the Phase 2b Randomized, Open-Label, Study of Lower Doses of Quizartinib in Subjects with FLT3-ITD Positive Relapsed Acute Myeloid Leukemia (AML): The purpose of this study is to assess the efficacy and safety of lower doses of quizartinib in the treatment of patients 18-years or older with relapsed/refractory FLT3 ITD positive AML to further improve the benefit:risk assessment of quizartinib.

This preliminary analysis is based on data available through May 28, 2013 with a minimum of eight weeks of follow up since the last subject first visit.  A total of 76 patients were enrolled from May 21, 2012 to March 27, 2013.  Median age for all patients was 55 (19-77) and 92% were FLT3-ITD(+).  35 patients remained in follow-up at the time of the analysis, and are currently censored for overall survival.  The following key information was presented:

For dose of 30mg:

  • The CRc rate was 47 percent (5 percent CR+CRp, 42 percent CRi)
  • The rate of HSCT after quizartinib use was 32 percent
  • The median overall survival was 20.7 weeks, with 16/38 patients censored as they remained in follow-up at the time of the analysis
  • Of the 12 patients who were bridged to HSCT, the median overall survival was 31 weeks
  • Grade 2 or greater QT prolongation was 11%, with a 5% grade 3 rate and no grade 4 events
  • For dose of 60mg:

  • The
    '/>"/>

  • SOURCE Ambit Biosciences
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Ambit Announces Participation At Oppenheimer 24th Annual Healthcare Conference
    2. Ambit Biosciences Provides Regulatory Update Following FDA Meeting Regarding Quizartinib (AC220)
    3. Ambit Biosciences to Announce Third Quarter 2013 Financial and Operating Results and Conference Call
    4. Ambit Biosciences Corporation Announces Second Quarter 2013 Operational Results
    5. Ambit Biosciences to Announce Second Quarter 2013 Operational Results and Conference Call
    6. Ambit Biosciences Announces Presentations of Data from Clinical Investigations of Quizartinib at the Annual Meeting of the American Society of Clinical Oncology
    7. Lo studio pubblicato su European Radiology esalta ulteriormente lutilizzo della tomosintesi al seno di Hologic nellambito dello screening del cancro con utilizzo della doppia lettura
    8. Ambit Biosciences Appoints David Parkinson, M.D., to Board of Directors
    9. Astellas and Ambit to End Collaboration for Joint Development and Commercialization of FLT3 Kinase Inhibitors
    10. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
    11. Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... Research and Markets  has announced the ... report to their offering. ... a hollow needle commonly used with a syringe to ... fluids from it. A hypodermic needle is used for ... cannot be ingested. Hypodermic needles are broadly classified into ...
    (Date:7/11/2014)... July 11, 2014  Australian drug delivery company, Phosphagenics ... has raised A$19.3 million via a placement of A$16.3 ... , the U.S., Asia and ... a share purchase plan (SPP) to be offered to ... made in two tranches. "This capital raising ...
    (Date:7/11/2014)... New York , July 11, 2014 ... by Transparency Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic ... Size, Share, Growth, Trends and Forecast, 2013-2019" the global ... in 2012 and is expected to grow at a ... an estimated value of USD 36.9 billion in 2019. ...
    Breaking Medicine Technology:Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6
    ... 31, 2011 Restorative Therapies, Inc., advances its new ... injury and paralysis with FDA clearance of the world,s ... system for stepping and standing. FES is ... activity and exercise not otherwise possible for individuals with ...
    ... Reportlinker.com announces that a new market research ... Global Surgical Incision Closures Industry ... This report analyzes the worldwide markets ... by the following product segments: Stapler Products ...
    Cached Medicine Technology:Restorative Therapies, Inc., Today Announced a Rehabilitation Breakthrough, the RT600 Functional Electrical Stimulation (FES) Stepper 2Global Surgical Incision Closures Industry 2Global Surgical Incision Closures Industry 3Global Surgical Incision Closures Industry 4Global Surgical Incision Closures Industry 5Global Surgical Incision Closures Industry 6Global Surgical Incision Closures Industry 7Global Surgical Incision Closures Industry 8Global Surgical Incision Closures Industry 9Global Surgical Incision Closures Industry 10Global Surgical Incision Closures Industry 11Global Surgical Incision Closures Industry 12Global Surgical Incision Closures Industry 13Global Surgical Incision Closures Industry 14Global Surgical Incision Closures Industry 15Global Surgical Incision Closures Industry 16Global Surgical Incision Closures Industry 17Global Surgical Incision Closures Industry 18Global Surgical Incision Closures Industry 19Global Surgical Incision Closures Industry 20Global Surgical Incision Closures Industry 21Global Surgical Incision Closures Industry 22Global Surgical Incision Closures Industry 23Global Surgical Incision Closures Industry 24
    (Date:7/14/2014)... A recent study published in the July 2014 issue ... Child and Adolescent Psychiatry confirms the validity of ... for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , In DSM-5, ... 7 in DSM-IV, has been raised to 12. As ... at 12, rather than an earlier age, to reflect ...
    (Date:7/14/2014)... years that have passed since acupuncture was first ... used to treat a number of physical, mental ... rehabilitation, headaches, menstrual cramps, asthma, carpal tunnel, fibromyalgia ... Now, a meta-analysis of randomized controlled trials which ... , the journal of The North American Menopause ...
    (Date:7/14/2014)... July 14, 2014 Last month Bromell ... their website. The webpage features more detailed information on ... including motorcycles, RVs, ATVs, and boats in the state ... this new feature to the website in order to ... helps encompass the purpose of the website, which is ...
    (Date:7/14/2014)... works could lead to the next generation of treatments ... forms when recently evolved genes are damaged, and cells ... , Astrobiologists Dr Charley Lineweaver from The Australian ... University teamed up with oncologist Dr Mark Vincent from ... model. , "The rapid proliferation of cancer cells ...
    (Date:7/14/2014)... July 14, 2014 The report ... Services [Physical Security, Life Safety, Facility Management], IT ... Forecast & Analysis (2014 - 2019)” defines and ... an in-depth analysis and forecasting of revenues. The ... various restraints and opportunities impacting it, along with ...
    Breaking Medicine News(10 mins):Health News:Bothered by hot flashes? Acupuncture might be the answer 2Health News:New theory turns cancer on its head 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 3Health News:Intelligent Building Automation Technologies Market Worth $74.8 Billion by 2019 - New Report by MarketsandMarkets 4
    ... Research Inc. (TSX: NRI), a Canadian drug development company ... that are delivered to and through the skin using ... its financial and operational results for the year and ... Key Corporate Developments:, - ...
    ... radiologists and referring, ... physicians and specialists , ... GE Healthcare,announced today in Asia the release of Centricity PACS Web ... is tightly,integrated to Centricity RIS/ PACS, which bring comprehensive detailed patient,history ...
    ... Nursing Productivity in the Treatment of Renal Disease , ... ... 2009 -- iSirona®, an innovative provider of data automation solutions ... agreement with NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer ...
    ... announces the implementation of its rehabilitation software by HealthPoint ... Southeast Missouri Hospital, a 269-bed regional medical complex serving ... functionality for electronically managing therapy documentation, scheduling, referrals, insurance ... ...
    ... , New web-based research has quantified the attractiveness of ... the features of one woman into 243 variations with ... waist widths. Then more than 34,000 people judged the ... exactly the same in all of the photos, researchers ...
    ... Modernizes TechnologyWASHINGTON, Feb. 26 President Obama,s first ... (VA) expands eligibility for health care to an ... years, meets the need for continued growth in ... Afghanistan and provides the resources to deliver quality ...
    Cached Medicine News:Health News:Nuvo announces 2008 fourth quarter and year-end financial results 2Health News:Nuvo announces 2008 fourth quarter and year-end financial results 3Health News:Nuvo announces 2008 fourth quarter and year-end financial results 4Health News:Nuvo announces 2008 fourth quarter and year-end financial results 5Health News:Nuvo announces 2008 fourth quarter and year-end financial results 6Health News:Nuvo announces 2008 fourth quarter and year-end financial results 7Health News:Nuvo announces 2008 fourth quarter and year-end financial results 8Health News:Nuvo announces 2008 fourth quarter and year-end financial results 9Health News:Nuvo announces 2008 fourth quarter and year-end financial results 10Health News:Nuvo announces 2008 fourth quarter and year-end financial results 11Health News:Nuvo announces 2008 fourth quarter and year-end financial results 12Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 2Health News:GE Healthcare Introduces New Web-Based Diagnostic Viewer with Workflow Integration and Streaming Technology for Hospitals in Asia 3Health News:iSirona Signs Reference Selling Agreement with NxStage 2Health News:Southeast Missouri Hospital Implements Chart Links Rehabilitation Software for Therapists 2Health News:Southeast Missouri Hospital Implements Chart Links Rehabilitation Software for Therapists 3Health News:Plastic and reconstructive surgery ... in brief 2Health News:President's 2010 Budget Request Strongly Supports VA Programs 2
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: